


# DoMore Diagnostics

AI-driven cancer prognostication



“ Despite decades of comprehensive research and large investments into gene sequencing, there are only a handful of useful prognostic and predictive markers. As a result, cancer patients do not receive the optimal treatment. We utilize the full potential of AI deep learning to develop scalable cancer markers that will improve and lower the cost of cancer treatment. ”

Torbjørn Furuset, MD, CEO and co-founder at DoMore Diagnostics

## About DoMore Diagnostics

DoMore Diagnostics has developed a technology that helps oncologists to identify who needs chemotherapy after the cancerous tumors have been removed; hence reducing the number of patients receiving unnecessary treatments. DoMore Diagnostics springs from a 5-year research project at the Institute for Cancer Genetics and Informatics at Oslo University Hospital. The research has gained recognition in *The Lancet*, the world's perhaps most prestigious medical journal.

[www.domorediagnostics.com](http://www.domorediagnostics.com)

## Key information

Founded: 2020  
CEO: Torbjørn Furuset, MD  
HQ: Oslo, Norway  
Impact theme: Well-being  
Industry: Health care

## Impact potential

5/5 | Impact-generating

## SDG targets contribution



## Net impact score

+50 % | +89 %<sup>1</sup>

1. Applying Norselab custom value set mapped to SDGs

# DoMore Diagnostics

## Sustainability challenges

### Cancer mortality

The International Agency for Research on Cancer (IARC) estimates that in 2020 colorectal cancer was the third most commonly diagnosed cancer globally, with nearly 2 million new cases. It was the third most common cancer in men and the second most common cancer in women. Colorectal cancer was also the second most common cause of cancer death worldwide, causing almost 1 million deaths.

### Cancer prognosis precision

Diagnostication methods may still be inaccurate and may not provide the most adapted treatment for every patient. This results in patients sometimes receiving unnecessary treatments. Faulty or inaccurate cancer prognosis is an economic cost to society, and a significant human cost for individuals.

## Theory of change

DoMore Diagnostics is on a mission to transform cancer diagnostics with artificial intelligence to improve patient care and make drug development more effective. Deep learning can be used to increase the prognostic value of cancer tissue biopsies. These new methods provide objective and precise prognostic information and can guide selection of therapy to avoid over- or undertreatment. It can also make cancer drug development more effective by ensuring more precise diagnosis and prognosis, enabling precision medicine.



Targets 3.4, 3.b

68%

Reduction in uncertain prognosis

90 million

Image tiles analyzed

15 000

Patients' data captured from 8 countries